At the time of this writing, Eli Lilly & Co. (LLY) is up 16.34% on the day, making it one of the biggest winners in the market today. The surge comes after a positive update from Bloomberg about Orforglipron, an experimental weight loss drug.
The results of the trial showed that the patient lost an average of 7.9% of his body weight over 40 weeks, and that Novo Nordisk’s Ozempic was shot at a significant margin. The news sent shockwaves through the market as investors and analysts alike realized that Lily could become a major player in the obesity drug market.
But what does this mean to you as an investor? Let’s break it down:
Numbers:
- Lly is up 16.34% today, making it one of the biggest winners in the market.
- The company’s stock price rose $120.08 to a new high of $854.98.
- Lily’s weight loss drug trial results show that patients lost an average of 7.9% of their body weight over a 40-week period, surpassing Novonordisk’s Ozempic shot.
context:
Lily has been working on developing her own weight loss medication for a while. These latest test results are an important step in the process. The company is confident that if Orforglipron is approved, it can be launched worldwide without supply constraints. This is a major advantage over the Ozempic shots of the Novo Nordisk.
risk:
While this news is certainly positive for Lily investors, there are still risks associated with investing in stocks. The company faces competition from other players in the market, including Pfizer and AstraZeneca.
Additionally, regulatory approvals for OrforGlipron are always a critical step for the company and there is always the risk that they may not receive the approvals they need to launch their products.
What’s next:
Lily says she hopes to submit Orforglipron for weight management by the end of this year, when a type 2 diabetes application is expected in 2026. The company must continue to work on completing the pill and navigation of regulatory hurdles before bringing it to the market.
Go ahead of the game:
Want to stay up to date with the latest stock news and trends? Sign up for our free SMS list Tap here. Then move on to the end of the game.
